Matheson


News and Insights

Print this page

Search News & Insights


Matheson Advises Zavante Therapeutics on its acquisition by Nabriva Therapeutics

AUTHOR(S): Patrick Spicer, Mark O’Sullivan, Fergus Bolster
KEY CONTACT(S): Patrick Spicer, Mark O’Sullivan, Fergus Bolster
PRACTICE AREA GROUP: Corporate, Mergers and Acquisitions
DATE: 29.08.2018

Matheson recently advised San Diego based Zavante Therapeutics on its acquisition by Irish registered, NASDAQ listed, Nabriva Therapeutics plc. in a deal that involved the issuance of upfront consideration in the form of Nabriva shares.

Nabriva is a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections.

Zavante is a biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients.

Zavante was advised by a Matheson team which included Corporate M&A Partners, Fergus Bolster and Patrick Spicer, West Coast based Tax Partner, Mark O’Sullivan and Tax Senior Associate, Vahan Tchrakian.

Fergus Bolster said:

“We are very pleased to have acted, in conjunction with US advisers, for Zavante on this latest M&A transaction in the pharmaceuticals space.  We, at Matheson, have particular expertise advising in relation to M&A and capital markets transactions involving equity issuances by Irish companies with US listings, and how to navigate the complexities where Irish and US securities and tax laws intersect.”

With a wealth of experience across our five partner led offices worldwide and a dedicated 100 person Corporate Department, Matheson has some of the most experienced corporate lawyers in Ireland and were named Ireland M&A Legal Adviser of the Year at the 2017 Mergermarket European M&A Awards.  Excellence matters and Matheson’s Corporate Department, led by 20 partners, has unparalleled experience in complex and innovative domestic and international corporate transactions across all industry sectors.

BACK TO LISTING



About cookies on our website

Following a revised EU directive on website cookies, each company based, or doing business, in the EU is required to notify users about the cookies used on their website.

Our site uses cookies to improve your experience of certain areas of the site and to allow the use of specific functionality like social media page sharing. You may delete and block all cookies from this site, but as a result parts of the site may not work as intended.

To find out more about what cookies are, which cookies we use on this website and how to delete and block cookies, please see our Which cookies we use page.

Click on the button below to accept the use of cookies on this website (this will prevent the dialogue box from appearing on future visits)